215 related articles for article (PubMed ID: 29296883)
1. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.
Francica JR; Zak DE; Linde C; Siena E; Johnson C; Juraska M; Yates NL; Gunn B; De Gregorio E; Flynn BJ; Valiante NM; Malyala P; Barnett SW; Sarkar P; Singh M; Jain S; Ackerman M; Alam M; Ferrari G; Salazar A; Tomaras GD; O'Hagan DT; Aderem A; Alter G; Seder RA
Blood Adv; 2017 Nov; 1(25):2329-2342. PubMed ID: 29296883
[TBL] [Abstract][Full Text] [Related]
2. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.
Liang F; Lindgren G; Sandgren KJ; Thompson EA; Francica JR; Seubert A; De Gregorio E; Barnett S; O'Hagan DT; Sullivan NJ; Koup RA; Seder RA; Loré K
Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592561
[TBL] [Abstract][Full Text] [Related]
3. Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.
Martinez P; Sundling C; O'Dell S; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Sci Rep; 2015 Mar; 5():8925. PubMed ID: 25762407
[TBL] [Abstract][Full Text] [Related]
4. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
5. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates.
Wille-Reece U; Flynn BJ; Loré K; Koup RA; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15190-4. PubMed ID: 16219698
[TBL] [Abstract][Full Text] [Related]
6. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
[TBL] [Abstract][Full Text] [Related]
7. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
8. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
[TBL] [Abstract][Full Text] [Related]
9. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
[TBL] [Abstract][Full Text] [Related]
10. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.
Grigoryan L; Lee A; Walls AC; Lai L; Franco B; Arunachalam PS; Feng Y; Luo W; Vanderheiden A; Floyd K; Wrenn S; Pettie D; Miranda MC; Kepl E; Ravichandran R; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; Coffman RL; Novack D; Kleanthous H; O'Hagan DT; van der Most R; McLellan JS; Suthar M; Veesler D; King NP; Pulendran B
NPJ Vaccines; 2022 May; 7(1):55. PubMed ID: 35606518
[TBL] [Abstract][Full Text] [Related]
11. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of long-lasting immunoprotective effect against Androctonus australis hector envenomation using safe antigens: Comparative role of MF59 and Alum adjuvants.
Nouri A; Laraba-Djebari F
Vaccine; 2015 Oct; 33(43):5756-5763. PubMed ID: 26419199
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans.
Xu S; Carpenter MC; Spreng RL; Neidich SD; Sarkar S; Tenney D; Goodman D; Sawant S; Jha S; Dunn B; Juliana McElrath M; Bekker V; Mudrak SV; Flinko R; Lewis GK; Ferrari G; Tomaras GD; Shen X; Ackerman ME
NPJ Vaccines; 2022 Aug; 7(1):90. PubMed ID: 35927399
[TBL] [Abstract][Full Text] [Related]
14. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.
Buonsanti C; Balocchi C; Harfouche C; Corrente F; Galli Stampino L; Mancini F; Tontini M; Malyala P; Bufali S; Baudner B; De Gregorio E; Valiante NM; O'Hagan DT; Rappuoli R; D'Oro U
Sci Rep; 2016 Jul; 6():29063. PubMed ID: 27439378
[TBL] [Abstract][Full Text] [Related]
15. Effect of apoptosis-associated speck-like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant.
Lee DK; Lee EY; Kim RH; Kwak HW; Kim JY; Kim H; Kang KW; Lee SM; Park JH; Chang J; Nam JH
Microbiol Immunol; 2018 Mar; 62(3):176-186. PubMed ID: 29315762
[TBL] [Abstract][Full Text] [Related]
16. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
[TBL] [Abstract][Full Text] [Related]
18. Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.
Loos C; Coccia M; Didierlaurent AM; Essaghir A; Fallon JK; Lauffenburger D; Luedemann C; Michell A; van der Most R; Zhu AL; Alter G; Burny W
NPJ Vaccines; 2023 Mar; 8(1):34. PubMed ID: 36890168
[TBL] [Abstract][Full Text] [Related]
19. HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.
Apostólico Jde S; Boscardin SB; Yamamoto MM; de Oliveira-Filho JN; Kalil J; Cunha-Neto E; Rosa DS
PLoS One; 2016; 11(1):e0145637. PubMed ID: 26727218
[TBL] [Abstract][Full Text] [Related]
20. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
